Ig Vena

Human Normal Immunoglobulin (IV), the active ingredient in Ig Vena, is an immunoglobulin presented as a solution for injection for intravenous use. It provides passive immunity and is employed to treat primary and secondary immunodeficiency disorders, immune‑mediated thrombocytopenia, and Kawasaki disease in appropriate patients.

GNH USA supplies Ig Vena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, including specialized immune‑deficiency units. The company adheres to stringent quality standards and provides regulatory‑approved products to support patient care across global markets.

Ig Vena, a pooled human immunoglobulin, replaces deficient antibodies and modulates immune activity in several conditions.

- Primary immunodeficiency diseases: restores IgG levels to reduce infection frequency. - Secondary immunodeficiency: provides passive immunity when antibody production is compromised. - Idiopathic thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑antibody activity. - Kawasaki disease: reduces inflammation and coronary artery complications in acute cases.

Adverse reactions to Ig Vena can vary from mild infusion‑related events to rare serious complications.

Common Side Effects: - Headache: mild to moderate pain during or after infusion. - Fever: transient elevation in temperature. - Nausea: mild gastrointestinal upset. - Fatigue: general tiredness following treatment.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction that can be life‑threatening. - Acute hemolysis: rapid breakdown of red blood cells. - Thromboembolic events: formation of blood clots in vessels. - Aseptic meningitis: inflammation of the meninges without infection.

Before administering Ig Vena, clinicians should consider several precautionary measures to ensure patient safety. - Assess immunoglobulin levels: confirm deficiency or indication before infusion. - Screen for IgA deficiency: patients with anti‑IgA antibodies may experience severe reactions. - Monitor vital signs: observe blood pressure, heart rate, and temperature during infusion. - Adjust infusion rate: start slowly and increase if no adverse reactions occur. - Review concomitant anticoagulants: assess bleeding risk when combined with anticoagulant therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ig Vena may interact with certain medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Live vaccines: concurrent use can reduce vaccine efficacy and increase infection risk. - High‑dose aspirin or NSAIDs: may increase bleeding tendency during infusion. - Rituximab: combined immunosuppression may heighten infection risk.

Moderate Interactions (Monitor Closely): - Corticosteroids: may augment immunosuppressive effect, requiring dose adjustment. - Anticoagulants (warfarin, heparin): monitor coagulation parameters. - Diuretics: watch for fluid shifts during large volume infusions.